Loading…
Matinas BioPharma Holdings, Inc. is projected to rise to $0.3928 by 2027, a +30% move from its current price of $0.3016. MTNB is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.2754 | $0.3013 | $0.3297 | -0.09% |
| Aug 6 | $0.2651 | $0.3011 | $0.3419 | -0.17% |
| Aug 7 | $0.2575 | $0.3008 | $0.3515 | -0.25% |
| Aug 8 | $0.2511 | $0.3006 | $0.3598 | -0.34% |
| Aug 9 | $0.2456 | $0.3003 | $0.3672 | -0.42% |
| Aug 10 | $0.2408 | $0.3001 | $0.374 | -0.51% |
| Aug 11 | $0.2363 | $0.2998 | $0.3803 | -0.59% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.2363 | $0.2998 | $0.3803 | -0.59% |
| Week 2 | $0.2129 | $0.298 | $0.4172 | -1.18% |
| Week 3 | $0.1962 | $0.2963 | $0.4473 | -1.77% |
| Week 4 | $0.183 | $0.2945 | $0.4739 | -2.35% |
| Week 5 | $0.172 | $0.2928 | $0.4983 | -2.93% |
| Week 6 | $0.1625 | $0.291 | $0.5211 | -3.51% |
| Week 7 | $0.1542 | $0.2893 | $0.5428 | -4.08% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company that identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. This platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.
Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It offers MAT2501, an orally administered formulation of amikacin.
The company was incorporated in 2013 and is based in Bedminster, New Jersey.
MTNB trades at a current price of $0.2938 with a market capitalization of $1.88M and a rank of 5451 by market cap.
The stock shows a NEUTRAL technical stance with RSI(14) at 40, and moving averages at SMA50 of $0.5922 and SMA200 of $0.73. These indicators place current price action in the context of nearby support and resistance levels.
Support is at $0.241 and resistance at $0.755. The 30-day price range spans from $0.1624 to $0.5314, and annualized volatility stands at 200%. The forecast sequence presents year-by-year targets, indicating a path of gradual upside with bullish sentiment emerging in later years (e.g., 2027 onward) and a notably bullish outlook by the 2030–2050 horizon.
A major floor 20.1% below — a decisive break under it would weaken the trend.
The nearest floor, 20.1% below — buyers have tended to step in here.
The nearest ceiling, 150.3% above — a clean break opens room to run.
A major ceiling 213.0% above — clearing it would confirm fresh momentum.
Key MTNB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MTNB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.3068 | Sell | $0.2998 | Buy |
| MA 10 | $0.2886 | Buy | $0.3178 | Sell |
| MA 20 | $0.4002 | Sell | $0.3862 | Sell |
| MA 50 | $0.5922 | Sell | $0.5078 | Sell |
| MA 100 | $0.5884 | Sell | $0.5916 | Sell |
| MA 200 | $0.73 | Sell | $0.7922 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 35.68 | Neutral |
| Stoch RSI (14) | 86.18 | Sell |
| CCI (20) | -53.44 | Neutral |
| Williams %R (14) | -54.31 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | -13.78 | Sell |
| Bollinger %B (20,2) | 0.33 | Neutral |
| Stochastic %K (14) | 45.69 | Neutral |
| TRIX (15) | -2.51 | Sell |
| Awesome (5,34) | -0.20 | Sell |
| Ultimate (7,14,28) | 45.56 | Neutral |
| Momentum (10) | -0.05 | Sell |
| Aroon Osc (25) | -40.00 | Sell |
| Hull MA (9) | 0.31 | Sell |
| ADX (14) | 30.35 | Sell |
| ATR (14) | 0.04 | Info |
The 30-day technical picture is NEUTRAL overall.
RSI(14) is 40, indicating neither overbought nor oversold conditions. The nearby moving averages are SMA50 at $0.5922 and SMA200 at $0.73, framing the near-term price action.
Key support sits at $0.241 and resistance at $0.755, with the 30-day range extending from $0.1624 to $0.5314.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.241 | $0.3016 | $0.3571 | 0% | Neutral | |
| $0.2862 | $0.3928 | $0.5825 | +30% | Bullish | |
| $0.3121 | $0.4555 | $0.7208 | +51% | Bullish | |
| $0.2651 | $0.4078 | $0.6779 | +35% | Bullish | |
| $0.2865 | $0.4621 | $0.80 | +53% | Bullish | |
| $0.2397 | $0.4042 | $0.7246 | +34% | Bullish | |
| $0.1895 | $0.3333 | $0.6162 | +11% | Neutral | |
| $0.2133 | $0.3907 | $0.7426 | +30% | Bullish | |
| $0.2528 | $0.4818 | $0.939 | +60% | Bullish | |
| $0.3001 | $0.5944 | $1.19 | +97% | Bullish | |
| $0.2416 | $0.5368 | $1.18 | +78% | Bullish | |
| $0.4757 | $1.06 | $2.43 | +251% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.241 | $0.3016 | $0.3302 | +0.00% |
| September 2026 | $0.2116 | $0.2573 | $0.3262 | -14.70% |
| October 2026 | $0.2264 | $0.2791 | $0.3612 | +8.49% |
| November 2026 | $0.223 | $0.278 | $0.3656 | -0.39% |
| December 2026 | $0.2124 | $0.2676 | $0.3571 | -3.73% |
Click any year to see its month-by-month MTNB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, MTNB is projected to trade between $0.241 and $0.3571, averaging $0.3016 — a potential gain of 0% from today's $0.3016. Price action looks broadly range-bound.
Matinas BioPharma Holdings, Inc.'s 2027 outlook centres on $0.3928, within a $0.2862 to $0.5825 range. That is up +30% on the projected 2026 average. That marks a +30% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, MTNB could reach as high as $0.7208, with a base case around $0.4555 and support toward $0.3121 — roughly +51% from $0.3016. Momentum favours further upside here.
Expect MTNB to range from $0.2651 to $0.6779 through 2029. The $0.4078 average target implies a +35% move from current prices. That is -10% versus the projected 2028 average. Buyers look set to stay in control over this stretch.
The MTNB price prediction for 2030 points to an average of $0.4621 (low $0.2865, high $0.80) — a potential gain of +53% on today's $0.3016. Momentum favours further upside here.
In 2031, MTNB is projected to trade between $0.2397 and $0.7246, averaging $0.4042 — a potential gain of +34% from today's $0.3016. That is -13% versus the projected 2030 average. Buyers look set to stay in control over this stretch.
Matinas BioPharma Holdings, Inc.'s 2032 outlook centres on $0.3333, within a $0.1895 to $0.6162 range. That is -18% versus the projected 2031 average. That marks a +11% change versus current levels. Price action looks broadly range-bound.
By 2033, MTNB could reach as high as $0.7426, with a base case around $0.3907 and support toward $0.2133 — roughly +30% from $0.3016. Buyers look set to stay in control over this stretch.
Expect MTNB to range from $0.2528 to $0.939 through 2034. The $0.4818 average target implies a +60% move from current prices. That is up +23% on the projected 2033 average. Momentum favours further upside here.
The MTNB price prediction for 2035 points to an average of $0.5944 (low $0.3001, high $1.19) — a potential gain of +97% on today's $0.3016. Buyers look set to stay in control over this stretch.
In 2040, MTNB is projected to trade between $0.2416 and $1.18, averaging $0.5368 — a potential gain of +78% from today's $0.3016. That is -10% versus the projected 2035 average. Momentum favours further upside here.
Matinas BioPharma Holdings, Inc.'s 2050 outlook centres on $1.06, within a $0.4757 to $2.43 range. That is up +97% on the projected 2040 average. That marks a +251% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in MTNB today (≈ 3,315.649867 MTNB) could be worth
$3,505.35
+$2,505.35 (+251%) by 2050 · US Dollar
Based on the average projected MTNB price of $1.06 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MTNBwould be worth at today's price.
$1,000 invested in MTNB on Jul 31, 2025 (≈ 1,136.363643 MTNB) would be worth
$342.73
-$657.27 (-65.7%) today · 0.34× · US Dollar
Based on a MTNB entry price of $0.88 vs. today's $0.3016.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.241 | $1,251.45 | +25.1% |
| 1 month ago | $0.631 | $477.97 | -52.2% |
| 3 months ago | $0.699 | $431.47 | -56.9% |
| 6 months ago | $0.601 | $501.83 | -49.8% |
| 1 year ago | $0.88 | $342.73 | -65.7% |
| All time (5.0y) ago | $39 | $7.73 | -99.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MTNB forecast.
Our base-case forecast reaches $0.60 around 2050.
Implied market cap at $0.60: $3.84M
The multi-year forecast shows a bullish trajectory over the longer term, with several years labeled BULLISH and a clear rise in average price across the horizon. In 2026 the average price is $0.2938 with a min of $0.241 and a max of $0.3483, and an ROI of 0%. The outlook strengthens in 2027 with an average of $0.3835 and a max of $0.5688, ROI 30.5%.
By 2028 the average reaches $0.4432 and the max $0.7014, ROI 50.8%.
In 2029 the average is $0.3971 (min $0.2582, max $0.6603), ROI 35.2%. The 2030 forecast shows an average of $0.4513 (min $0.2798, max $0.7814), ROI 53.6% and a bullish sentiment. By 2031 the average is $0.393 (min $0.2331, max $0.7047), ROI 33.8% with bullish sentiment, then 2032 at an average of $0.324 (min $0.1842, max $0.5991), ROI 10.3% with neutral sentiment.
Further out, 2033 carries an average of $0.3821 (min $0.2086, max $0.7262), ROI 30% and bullish sentiment; 2034 shows $0.4693 average (min $0.2463, max $0.9148), ROI 59.7% and bullish sentiment; 2035 yields $0.5789 average (min $0.2922, max $1.15), ROI 97% and bullish sentiment. The horizon extends to 2040 with an average of $0.5214 (min $0.2346, max $1.14), ROI 77.5% and bullish sentiment, and to 2050 with an average of $1.03 (min $0.4641, max $2.37), ROI 251.1% and bullish sentiment.
These figures illustrate a long-run bullish tilt, but they are estimates and not guarantees. The forecast contains inherent uncertainty and depends on multiple factors including market dynamics and clinical progress for MAT therapies.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $0.4513 with a min of $0.2798 and a max of $0.7814, and an ROI of 53.6%. The sentiment is BULLISH.
The projection shows a bullish path in many years, with rising averages and a bullish sentiment in the later years. However, MTNB is a micro-cap and carries inherent risk, and these figures are estimates, not guarantees.
The forecast maximum by 2050 is $2.37, with a 2050 average of $1.03 and ROI of 251.1%, indicating a potential to exceed $2 under the stated conditions.
The 30-day range is $0.1624 to $0.5314.
Current price is $0.2938 and market cap is $1.88M.
Matinas BioPharma Holdings, Inc. Community Discussion
0Share your Matinas BioPharma Holdings, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.